Fig. 9
From: LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC
The combination of LCL161 and paclitaxel has strong antitumor activity in vivo. Approximately 2 × 106 H460 cells were injected subcutaneously into each nude mouse. After tumor formation, 10 mg/kg LCL161 and/or 20 mg/kg paclitaxel were intraperitoneally injected into the mice. a Typical images of mice with H460 xenografts in the control, LCL161, paclitaxel and drug combination groups. Curves of tumor growth (b) and body weight (c) for H460 xenografts with drug treatment. The tumor volume and body weight of the mice are provided as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001